Silence Therapeutics plc (SLN) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Silence Therapeutics plc (SLN) Healthcare & Pipeline Overview

Silence Therapeutics plc is a London-based biotechnology company specializing in novel RNA therapeutics for hematological, cardiovascular, and rare metabolic conditions. Utilizing its mRNAi GOLD platform, the company develops targeted short interfering RNA molecules to address disease-associated genes, advancing multiple product candidates through early-stage clinical trials and strategic collaborations with major pharmaceutical partners.

What Is the Investment Thesis for SLN?

Silence Therapeutics plc presents an investment thesis centered on its innovative mRNAi GOLD platform and a pipeline of early-stage RNA therapeutics addressing significant unmet medical needs. The company's strategic collaborations with AstraZeneca PLC, Mallinckrodt Pharma IP Trading DAC, and Hansoh Pharmaceutical Group Company Limited provide external validation of its technology and potential for future milestone payments and royalties, diversifying its revenue potential beyond internal product commercialization. Key value drivers include the progression of SLN360 for cardiovascular disease and SLN124 for hematological disorders through clinical trials. Positive data readouts from these Phase I trials could serve as significant growth catalysts, de-risking the platform and attracting further partnerships. While the company currently operates at a substantial negative profit margin of -9243.0% and a market capitalization of $570M, typical for early-stage biotechnology firms, its gross margin of 66.4% indicates strong potential profitability if product development succeeds. The high beta of 1.48 reflects its sensitivity to market fluctuations, characteristic of a development-stage biotech. The long-term value is tied to the successful advancement and eventual commercialization of its RNAi drug candidates, which could address large market opportunities in cardiovascular and rare disease segments.

Based on FMP financials and quantitative analysis

SLN Key Highlights

• Market capitalization stands at $0.29 billion, reflecting its status as an early-stage biotechnology company focused on research and development.
• Reported a profit margin of -9243.0%, which is characteristic of biotechnology firms in the clinical development phase, heavily investing in R&D.
• Maintained a gross margin of 66.4%, indicating a strong potential for profitability in its core operations should product commercialization be achieved.
• The company's Beta is 1.48, suggesting higher volatility compared to the broader market, typical for a biotechnology stock with significant clinical trial catalysts.
• Currently has no dividend yield, consistent with its growth-oriented strategy and reinvestment of capital into pipeline development.

Who Are SLN's Competitors?

SLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SLN's Key Strengths?

• Proprietary mRNAi GOLD platform offers targeted gene silencing capabilities.
• Strategic collaborations with major pharmaceutical companies like AstraZeneca and Mallinckrodt.
• Pipeline includes candidates for high-need areas such as cardiovascular and rare hematological diseases.
• Strong gross margin of 66.4% indicates potential for profitability upon commercialization.

What Are SLN's Weaknesses?

• Significant negative profit margin (-9243.0%) reflecting high R&D costs typical of early-stage biotech.
• All product candidates are in early-stage (Phase I) clinical trials, implying high development risk and long timelines.
• Relatively small company with 116 employees, potentially limiting internal resource allocation compared to larger competitors.
• Reliance on successful clinical trial outcomes for future revenue generation.

What Could Drive SLN Stock Higher?

• **Phase I Clinical Trial Data Readout for SLN360:** Positive efficacy and safety data from the ongoing Phase I trial of SLN360 for cardiovascular disease with high lipoprotein could significantly de-risk the program and attract further investment or partnership interest, potentially leading to progression into later-stage trials.
• **Phase I Clinical Trial Data Readout for SLN124 (Thalassemia/MDS):** Favorable results from the ongoing Phase I trials for SLN124 in non-transfusion dependent thalassemia and myelodysplastic syndrome would be a critical validation for the company's platform in hematological indications, opening pathways for further development and potential orphan drug designations.
• **Advancement of Partnered Programs with AstraZeneca:** Continued progress in the discovery and development of siRNA therapeutics under the collaboration agreement with AstraZeneca PLC, particularly the identification of new clinical candidates, could trigger milestone payments and validate the broad applicability of Silence's mRNAi GOLD platform.
• **Initiation of Phase II Trials for Lead Candidates:** The successful completion of Phase I trials and subsequent initiation of Phase II trials for either SLN360 or SLN124 would mark a significant step forward in their development, indicating increased confidence in their therapeutic potential and moving them closer to potential commercialization.

What Are the Key Risks for SLN?

• Financial-distress signal — its Altman Z-Score of -4.39 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• **Clinical Trial Failure:** As all current product candidates (SLN360, SLN124) are in early-stage (Phase I) clinical trials, there is a high risk of failure to demonstrate sufficient efficacy or safety, which could lead to program termination and significant financial loss.
• **Funding and Liquidity Risk:** As an early-stage biotechnology company with a negative profit margin, Silence Therapeutics is reliant on external funding, including equity financing and collaboration payments, to support its extensive R&D activities. Failure to secure adequate funding could impede pipeline progression.
• **Regulatory Approval Risk:** Even with positive clinical data, there is no guarantee that Silence Therapeutics' drug candidates will receive regulatory approval from health authorities like the FDA or EMA, a process that is lengthy, complex, and subject to stringent requirements.
• **Competition in RNA Therapeutics:** The RNA therapeutics market is highly competitive, with numerous large pharmaceutical companies and other biotech firms developing similar technologies. This intense competition could impact market share, pricing, and the ability to attract partnerships or talent.
• **Intellectual Property Infringement or Loss:** The company's success heavily depends on its ability to protect its proprietary mRNAi GOLD platform and drug candidates through patents. Any challenges to its intellectual property or inability to obtain new patents could severely undermine its competitive position.

What Are the Growth Opportunities for SLN?

• **Advancement of SLN360 in Cardiovascular Disease:** SLN360, currently in Phase I clinical trials, targets cardiovascular disease with high lipoprotein. The global market for cardiovascular disease treatments is substantial, projected to reach over $150 billion by the early 2030s. Successful progression through clinical phases and positive efficacy data could unlock a significant market opportunity, particularly given the high prevalence and unmet need for novel lipid-lowering therapies. The timeline for Phase II and III trials and potential commercialization extends several years, but positive early data could attract further investment or partnership interest, validating Silence's platform for broad application.
• **Expansion of SLN124 Indications:** SLN124 is in Phase I clinical trials for non-transfusion dependent thalassemia and myelodysplastic syndrome, with additional development for polycythemia vera. These represent rare and orphan indications, which often benefit from expedited regulatory pathways and premium pricing. The global market for rare disease therapeutics is growing, estimated to exceed $250 billion by 2027. Expanding SLN124's utility across multiple hematological disorders maximizes its market potential and addresses critical unmet needs in patient populations with limited treatment options. Each successful indication adds a distinct revenue stream.
• **Leveraging Strategic Collaborations for Pipeline Expansion:** Silence Therapeutics has active collaboration agreements with AstraZeneca PLC, Mallinckrodt Pharma IP Trading DAC, and Hansoh Pharmaceutical Group Company Limited. These partnerships not only provide non-dilutive funding through milestone payments but also expand the reach of Silence's mRNAi GOLD platform into new therapeutic areas, such as renal, metabolic, respiratory, and complement-mediated disorders. Each collaboration has the potential to yield multiple product candidates, significantly broadening Silence's pipeline without direct R&D investment. The long-term value lies in potential future royalties from successful partnered programs, with timelines extending over the next decade.
• **Platform Validation and New Target Identification:** The continued success of Silence's mRNAi GOLD platform in generating viable clinical candidates like SLN360 and SLN124 enhances its credibility and attractiveness for future partnerships. As the platform demonstrates its ability to accurately target specific disease-associated genes, particularly in the liver, it opens doors for identifying and pursuing new, previously intractable targets. The RNAi therapeutic market is still nascent with vast untapped potential, and a validated platform can quickly pivot to emerging disease areas or new biological insights, offering a flexible growth pathway over the next 5-10 years.
• **Geographic Market Penetration through Partnerships:** The collaboration with Hansoh Pharmaceutical Group Company Limited specifically targets undisclosed siRNAs leveraging Silence's platform, likely with a focus on the Chinese market. China represents one of the fastest-growing pharmaceutical markets globally, with significant demand for innovative therapies. This partnership provides a strategic entry point into a major international market without the need for Silence to build out its own extensive local infrastructure. Successful development and commercialization of these partnered programs in China could provide substantial revenue streams and global market diversification over the medium to long term, enhancing overall company value.

What Opportunities Does SLN Have?

• Successful progression of SLN360 and SLN124 through clinical trials could unlock substantial market value.
• Expansion of the mRNAi GOLD platform into new therapeutic areas through existing or new partnerships.
• Potential for orphan drug designations for rare disease indications, offering market exclusivity and incentives.
• Growth in the broader RNA therapeutics market driven by technological advancements and increasing disease understanding.

What Threats Does SLN Face?

• High failure rates associated with clinical trials in the biotechnology industry.
• Intense competition from larger pharmaceutical companies and other biotech firms developing RNA-based therapies.
• Regulatory hurdles and lengthy approval processes for novel drug candidates.
• Patent expiry or challenges to intellectual property could erode competitive advantage.

What Are SLN's Competitive Advantages?

• **Proprietary mRNAi GOLD Platform:** A specialized oligonucleotide discovery platform designed for accurate targeting of disease-associated genes in the liver, providing a technological edge.
• **Deep Expertise in RNA Interference:** Specialized scientific knowledge and intellectual property surrounding siRNA design and application for gene silencing.
• **Strategic Pharmaceutical Collaborations:** Partnerships with major global pharmaceutical companies validate the technology and provide access to resources, development expertise, and broader market reach.
• **Early-Stage Pipeline in High-Need Areas:** Focus on rare diseases and significant cardiovascular conditions where unmet medical needs are high, potentially leading to orphan drug designations and accelerated approvals.

What Does SLN Do?

Silence Therapeutics plc, headquartered in London, United Kingdom, is a pioneering biotechnology company dedicated to the discovery and development of innovative ribonucleic acid (RNA) therapeutics. The company's core mission revolves around addressing unmet medical needs in significant therapeutic areas, including hematology, cardiovascular diseases, and various rare and metabolic indications. Founded as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007, reflecting its sharpened focus on RNA interference (RNAi) technology. At the heart of Silence Therapeutics' approach is its proprietary mRNAi GalNAc Oligonucleotide Discovery platform. This advanced platform is engineered to precisely target specific disease-associated genes primarily within the liver, offering a highly selective mechanism for therapeutic intervention. The company designs short interfering RNA (siRNA) molecules that harness the body's natural RNA interference pathway. This mechanism allows for the degradation of messenger RNA (mRNA) molecules that encode specific targeted disease-associated proteins within a cell, thereby effectively 'silencing' the production of harmful proteins. Silence Therapeutics' pipeline features several promising product candidates. SLN360 is currently in Phase I clinical trials, targeting cardiovascular disease characterized by high lipoprotein levels. SLN124 is also in Phase I clinical trials, being developed for the treatment of non-transfusion dependent thalassemia and myelodysplastic syndrome, with an additional indication for polycythemia vera. Beyond its internal pipeline, Silence Therapeutics has established significant collaboration agreements that validate its platform and expand its development capabilities. These include a strategic partnership with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics across cardiovascular, renal, metabolic, and respiratory diseases. Another key collaboration is with Mallinckrodt Pharma IP Trading DAC, focused on developing RNAi drug targets to silence the complement cascade in complement-mediated disorders. Furthermore, the company has partnered with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets, leveraging Silence's mRNAi GOLD platform. With 116 employees, Silence Therapeutics is positioned as an innovator in the rapidly evolving field of RNA therapeutics, aiming to bring transformative treatments to patients worldwide.

What Products and Services Does SLN Offer?

• Discovers and develops novel ribonucleic acid (RNA) therapeutics.
• Focuses on treatments for hematology, cardiovascular, and rare/metabolic indications.
• Utilizes its proprietary mRNAi GalNAc Oligonucleotide Discovery platform.
• Designs short interfering RNA (siRNA) molecules to harness the body's natural RNA interference mechanism.
• Degrades messenger RNA (mRNA) molecules that encode specific disease-associated proteins.
• Advances product candidates like SLN360 (cardiovascular disease) and SLN124 (thalassemia, myelodysplastic syndrome, polycythemia vera) through clinical trials.
• Engages in collaboration agreements with major pharmaceutical companies like AstraZeneca and Mallinckrodt for broader drug development.
• Headquartered in London, United Kingdom, with a team of 116 employees.

How Does SLN Make Money?

• **Drug Discovery and Development:** Invests in R&D to identify and develop novel RNAi therapeutics for various diseases.
• **Clinical Pipeline Advancement:** Progresses proprietary drug candidates through preclinical and clinical trial phases (e.g., SLN360, SLN124).
• **Strategic Partnerships and Collaborations:** Enters into agreements with larger pharmaceutical companies, receiving upfront payments, milestone payments, and potential future royalties on commercialized products.
• **Platform Licensing:** Potentially licenses its mRNAi GOLD platform to partners for the development of their own RNAi drug targets.

What Industry Does SLN Operate In?

Silence Therapeutics plc operates within the dynamic and rapidly evolving Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intense research and development, long product development cycles, and significant regulatory hurdles. The broader RNA therapeutics market, in which Silence Therapeutics is a key player, is experiencing substantial growth, driven by advancements in gene-silencing technologies and increasing understanding of genetic diseases. Silence Therapeutics distinguishes itself through its proprietary mRNAi GOLD platform, which focuses on targeted gene silencing in the liver using short interfering RNA (siRNA) molecules. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms also developing RNA-based therapies, particularly in areas like cardiovascular, rare, and metabolic diseases. The company's strategic collaborations with AstraZeneca and Mallinckrodt underscore the industry trend towards partnerships to share development costs and leverage specialized platforms. Success in this industry is heavily reliant on clinical trial outcomes and the ability to secure intellectual property, positioning Silence Therapeutics within a high-risk, high-reward segment of the healthcare market.

Who Are SLN's Key Customers?

• **Patients:** Ultimately, individuals suffering from hematological, cardiovascular, and rare/metabolic diseases that Silence's therapies aim to treat.
• **Healthcare Providers:** Physicians and hospitals who would prescribe and administer Silence's approved drugs.
• **Pharmaceutical Partners:** Companies like AstraZeneca, Mallinckrodt, and Hansoh, which collaborate on drug discovery and development, leveraging Silence's platform and expertise.

How Silence Therapeutics plc Is Valued

Silence Therapeutics plc carries a market capitalization of $570M, placing it in the small-cap category. Relative to its peer group, SLN's quantitative score of 58/100 is below the peer average of 84/100.

Company Profile

Silence Therapeutics plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Iain Gladstone Ross. SLN has traded publicly since 2020.

Key Financial Metrics

Return on assets is -74.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Silence Therapeutics plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.39 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Silence Therapeutics plc revenue of about $3.3M for fiscal 2026, with EPS near $-0.53. The estimate reflects 5 contributing analysts.

SLN Financials

SLN Latest News

SLN Analyst Consensus

SLN MoonshotScore

Silence Therapeutics plc Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources